Pharmaceuticals company Lincoln Pharmaceuticals announced Q1FY26 results Total Income: Rs 169.34 crore compared to Rs 157.69 crore during Q1FY25, change 7.39%. EBITDA: Rs 39.08 crore compared to Rs 33.14 crore during Q1FY25, change 17.92%. PBT: Rs 35.39 crore compared to Rs 29.48 crore during Q1FY25, change 20.05%. PAT: Rs 27.70 crore compared to Rs 23.69 crore during Q1FY25, change 16.93%. EPS: Rs 13.82 for Q1FY26. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said: Many countries had been added for the Cephalosporin plant products and product registration will be offered from these countries. During the Q1FY26 company had started Bulk Drug Manufacturing Plant. For which product approval had been received for 10 products and others are under process. At present company had plant to invest Rs 4 crore for this plant from internal accruals of the company. The company's growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company's liquidity remains solid. Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2-3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion. Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; IS0-900I:2015, IS0-1400I:2015 and IS0-4500 I :20 18. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development. Result PDF
Pharmaceuticals company Lincoln Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: For the Quarter ended in March 2025, company reported a standalone net profit of Rs 11.62 crore. EBITDA of Rs 19.84 crore and Total Income from operations at Rs 161.30 crore. EPS for Q4FY25 was at Rs 5.78 per share. FY25 Financial Highlights: Lincoln Pharmaceuticals reported a standalone net profit of Rs 82.44 crore for the FY25 ended March 2025 as against net profit of Rs 93.37 crore FY24. Total Income from operations for the FY25 was reported at Rs 645.71 crore over previous fiscal's same period revenue from operations of Rs 614.97 crore. Company reported EBITDA of Rs 123.97 in FY25 as compared to Rs 134.33 crore EBITDA in the corresponding period last year. EPS for FY25 was at Rs 41.1 per share. Company has recommended a dividend of 18 %, Rs 1.80 per share on the face value of Rs 10 per share for the FY 2024-25. Commenting on the Q4 and FY25 performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said, "Lincoln Pharmaceuticals has delivered consistent profit growth from FY13 through FY24 - a testament to our sound business fundamentals and execution capabilities. Company remain committed to net debt-free and continue to leverage strategic product launches in both domestic and international markets to strengthen our market presence. We are committed to significantly improve our growth going forward. With a clear focus on operational excellence and geographic expansion, we are well-positioned to achieve our Rs 750 crore revenue target by FY26." Result PDF
Pharmaceuticals company Lincoln Pharmaceuticals announced Q3FY25 results Revenue: Rs 146.55 crore compared to Rs 146.45 crore during Q3FY24, change 0.07%. EBITDA: Rs 32.63 crore compared to Rs 40.68 crore during Q3FY24, change -19.79%. PBT: Rs 28.68 crore compared to Rs 37.71 crore during Q3FY24, change -23.95%. PAT: Rs 20.77 crore compared to Rs 28.04 crore during Q3FY24, change -25.93%. EPS: Rs 10.37 for Q3FY25. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said: "We are pleased to report strong growth across all business verticals in the first nine months of FY25, with a vision to achieve record revenue, EBITDA, and net profit for the full year. Company aims to maintain a steady grow while maintaining a net debt-free status. Our new product launches in domestic and export markets have boosted growth and market presence. Driven by strategic initiatives, operational excellence, and geographic expansion, we are on track to achieve Rs. 750 crore revenue target by FY26. Notably, we are among the few companies with consistent profit growth from FY13 to FY24." Result PDF
Pharmaceuticals company Lincoln Pharmaceuticals announced H1FY25 results Total Income: Rs 328.88 crore compared to Rs 307.99 crore during H1FY24, change 6.78%. EBITDA: Rs 71.50 crore compared to Rs 68.25 crore during H1FY24, change 4.76%. Profit before Tax: Rs 64.26 crore compared to Rs 62.32 crore during H1FY24, change 3.11%. PAT: Rs 50.03 crore compared to Rs 46.52 crore during H1FY24, change 7.55%. EPS: Rs 24.96 for H1FY25. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said: “We are pleased to report continued strong growth across all business verticals H1FY25, while maintaining a net debt-free status. Our new product launches in domestic and export markets have strengthened our market presence and accelerated growth, positioning us for even better performance during the second half of the year. Through a combination of robust growth initiatives, highquality products, geographic expansion, and operational improvements, we are on track to achieve our ambitious Rs 750 crore revenue target by FY26. Notably, we are among a select group of companies that have consistently achieved profit growth every year from FY13 to FY24.” Result PDF